Hypophosphatemia-mediated hypotension in transgenic mice overexpressing human FGF-23.
Fibroblast growth factor-23 (FGF-23) is a potent circulating phosphaturic factor associated with renal phosphate wasting. The effects of FGF-23 on skeletal and phosphate homeostasis have been investigated widely; however, the effect of FGF-23 on the cardiovascular system (CVS) is unknown. To assess whether FGF-23 influences the function and structure of the CVS and whether the effect of FGF-23 on the CVS is mediated by FGF receptors directly or indirectly by hypophosphatemia, FGF-23 transgenic mice and their wild-type littermates were fed a normal diet or a high-phosphate diet comprising a normal diet plus 1.25% phosphate in drinking water from weaning for 5 wk, and the phenotypes of the CVS were compared between FGF-23 transgenic mice and their wild-type littermates on the same diet. At the end of this time period, transgenic animals on the normal diet developed hypotension. The left ventricle was appropriately hypertrophic, and plasma catecholamine and renin-angiotensin system components were upregulated, indicating compensatory mechanisms in response to the hypotension. Transgenic mice also exhibited an impaired vascular reactivity and a downregulation of vasoconstrictor receptor gene expression, possibly as pathogenetic factors contributing to the hypotension. The high-phosphate diet improved the hypophosphatemia, resulting in a rescue of the cardiovascular phenotype. This study demonstrates that FGF-23 overexpression can result in abnormalities in the CVS and that the effect of FGF-23 overexpression on the CVS is mediated by the secondary severe hypophosphatemia.
Liu
Peidang
P
Department of Anatomy, Laboratory of Reproductive Medicine and The Research Center for Bone and Stem Cells, Nanjing Medical University, Nanjing, China.
Bai
Xiuying
X
Wang
Heming
H
Karaplis
Andrew
A
Goltzman
David
D
Miao
Dengshun
D
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000097:blood; D004032:Diet; D004305:Dose-Response Relationship, Drug; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D017674:Hypophosphatemia / Q000150:complications* / Q000178:diet therapy / Q000378:metabolism / Q000503:physiopathology; D007022:Hypotension / Q000209:etiology* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D010641:Phenotype; D010710:Phosphates / Q000008:administration & dosage; D012333:RNA, Messenger / Q000378:metabolism; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics; D018340:Receptors, Adrenergic, alpha-1 / Q000235:genetics; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000235:genetics; D015854:Up-Regulation; D014661:Vasoconstriction / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D016277:Ventricular Function, Left
D002395:Catecholamines; C000717427:FGF23 protein, human; C000717428:Fgf23 protein, mouse; D010710:Phosphates; D012333:RNA, Messenger; D044140:Receptor, Angiotensin, Type 1; D018340:Receptors, Adrenergic, alpha-1; D017468:Receptors, Fibroblast Growth Factor; D014662:Vasoconstrictor Agents; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23